IL305952A - Melanocortin subtype 2 receptor (MC2R) antagonist for disease treatment - Google Patents

Melanocortin subtype 2 receptor (MC2R) antagonist for disease treatment

Info

Publication number
IL305952A
IL305952A IL305952A IL30595223A IL305952A IL 305952 A IL305952 A IL 305952A IL 305952 A IL305952 A IL 305952A IL 30595223 A IL30595223 A IL 30595223A IL 305952 A IL305952 A IL 305952A
Authority
IL
Israel
Prior art keywords
compound
solvate
pharmaceutically acceptable
acceptable salt
disease
Prior art date
Application number
IL305952A
Other languages
English (en)
Hebrew (he)
Inventor
Christine Ferrara-Cook
Alan S Krasner
Original Assignee
Crinetics Pharmaceuticals Inc
Ferrara Cook Christine
Alan S Krasner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crinetics Pharmaceuticals Inc, Ferrara Cook Christine, Alan S Krasner filed Critical Crinetics Pharmaceuticals Inc
Publication of IL305952A publication Critical patent/IL305952A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL305952A 2021-03-19 2022-03-16 Melanocortin subtype 2 receptor (MC2R) antagonist for disease treatment IL305952A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163163310P 2021-03-19 2021-03-19
US202263298571P 2022-01-11 2022-01-11
PCT/US2022/020543 WO2022197798A1 (en) 2021-03-19 2022-03-16 Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease

Publications (1)

Publication Number Publication Date
IL305952A true IL305952A (en) 2023-11-01

Family

ID=83321094

Family Applications (1)

Application Number Title Priority Date Filing Date
IL305952A IL305952A (en) 2021-03-19 2022-03-16 Melanocortin subtype 2 receptor (MC2R) antagonist for disease treatment

Country Status (10)

Country Link
US (2) US12280046B2 (https=)
EP (1) EP4308553A4 (https=)
JP (2) JP2024510260A (https=)
KR (1) KR20230159443A (https=)
AU (1) AU2022240609A1 (https=)
BR (1) BR112023018816A2 (https=)
CA (1) CA3211644A1 (https=)
IL (1) IL305952A (https=)
MX (1) MX2023010897A (https=)
WO (1) WO2022197798A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019280689B2 (en) 2018-06-05 2024-09-05 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
AU2022240609A1 (en) 2021-03-19 2023-09-28 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease
CN120344523A (zh) * 2022-12-16 2025-07-18 克林提克斯医药股份有限公司 结晶黑皮质素亚型-2受体(mc2r)拮抗剂
WO2024242979A1 (en) * 2023-05-19 2024-11-28 Crinetics Pharmaceuticals, Inc. Compositions and methods for the treatment of congenital adrenal hyperplasia

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284956A (en) 1988-09-06 1994-02-08 Hoffmann-La Roche Inc. Liquid crystalline mixtures containing 2-(2-fluorophenyl) pyridines
WO1999064002A1 (en) 1998-06-11 1999-12-16 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
CA2377369A1 (en) 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
US6890940B2 (en) 2001-06-29 2005-05-10 Kowa Co., Ltd. Bis(2-aryl-5-pyridyl) derivatives
US7115607B2 (en) 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
EP1465867A1 (en) 2001-10-09 2004-10-13 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
KR20040058307A (ko) 2001-11-26 2004-07-03 쉐링 코포레이션 비만 및 ｃｎｓ 장애를 치료하기 위한 피페리딘계 ｍｃｈ길항제
US7105489B2 (en) 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
AU2003216274A1 (en) 2002-02-11 2003-09-04 Neurocrine Biosciences, Inc. Pyrrole derivatives as ligands of melanocortin receptors
AU2003230367A1 (en) 2002-05-10 2003-11-11 Neurocrine Biosciences, Inc. Substituted piperazine as melanocortin receptors ligands
WO2004081643A1 (en) 2002-12-20 2004-09-23 Kaiser Aerospace & Electronics Corp. Lenslet array with polarization conversion
EP1460073A1 (en) 2003-03-20 2004-09-22 MyoContract Ltd. Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
RS53252B (sr) 2003-08-11 2014-08-29 F.Hoffmann-La Roche Ag. Piperazin sa or-supstituisanom fenil grupom i njihova upotreba kao inhibitora glyt1
CN1874777B (zh) 2003-09-09 2012-07-04 弗·哈夫曼-拉罗切有限公司 作为甘氨酸摄取抑制剂用于治疗精神病的1-(2-氨基-苯甲酰基)-哌嗪衍生物
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
US20050192286A1 (en) 2003-10-22 2005-09-01 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
US20050119252A1 (en) 2003-10-22 2005-06-02 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
TW200716594A (en) 2005-04-18 2007-05-01 Neurogen Corp Substituted heteroaryl CB1 antagonists
AU2006304305B2 (en) 2005-10-18 2010-04-01 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
RU2303597C1 (ru) 2006-05-12 2007-07-27 Иващенко Андрей Александрович Фармацевтическая композиция, способы ее получения и применения
HRP20100516T1 (hr) 2006-09-20 2010-10-31 Eli Lilly And Company Tiazolpirazolopirimidini kao antagonisti receptora crf1
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
PL2344474T3 (pl) 2008-09-02 2016-03-31 Novartis Ag Pochodne pikolinamidu jako inhibitory kinaz
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI598337B (zh) 2009-06-29 2017-09-11 阿吉歐斯製藥公司 治療化合物及組成物
WO2012163354A1 (en) 2011-05-31 2012-12-06 Linak A/S Actuator
EP4691556A3 (en) 2014-12-19 2026-04-29 H. Lundbeck A/S Humanized anti-acth antibodies and use thereof
EP3199156A1 (de) 2016-02-01 2017-08-02 Heinrich-Heine-Universität Düsseldorf Verwendung von glycin-transporter-1-antagonisten als zentralnervöse analgetika
WO2018003962A1 (ja) 2016-06-30 2018-01-04 国立研究開発法人理化学研究所 新規化合物又はその薬理学的に許容される塩
WO2019014460A1 (en) 2017-07-12 2019-01-17 The Brigham And Women's Hospital, Inc. MOLECULES ENHANCING EAAT2
SG11202003407VA (en) 2017-10-17 2020-05-28 Merck Patent Gmbh PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
AU2019280689B2 (en) 2018-06-05 2024-09-05 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
US20220023266A1 (en) 2018-12-07 2022-01-27 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
US12479825B2 (en) 2019-11-07 2025-11-25 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
CA3164117A1 (en) 2019-12-18 2021-06-24 Crinetics Pharmaceuticals, Inc. Gem-disubstituted piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
ES3032933T3 (en) 2019-12-23 2025-07-29 Crinetics Pharmaceuticals Inc Spirocyclic piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
KR20240023691A (ko) 2020-08-12 2024-02-22 스프루스 바이오사이언시스 인코포레이티드 다낭성 난소 증후군을 치료하기 위한 방법 및 조성물
AU2022240609A1 (en) 2021-03-19 2023-09-28 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease
WO2023163945A1 (en) 2022-02-23 2023-08-31 Crinetics Pharmaceuticals, Inc. Treatment of congenital adrenal hyperplasia and polycystic ovary syndrome
CN120344523A (zh) 2022-12-16 2025-07-18 克林提克斯医药股份有限公司 结晶黑皮质素亚型-2受体(mc2r)拮抗剂

Also Published As

Publication number Publication date
US20250367190A1 (en) 2025-12-04
WO2022197798A1 (en) 2022-09-22
JP2026009936A (ja) 2026-01-21
EP4308553A1 (en) 2024-01-24
US20220313691A1 (en) 2022-10-06
CA3211644A1 (en) 2022-09-22
TW202302108A (zh) 2023-01-16
KR20230159443A (ko) 2023-11-21
MX2023010897A (es) 2023-09-27
AU2022240609A1 (en) 2023-09-28
US12280046B2 (en) 2025-04-22
BR112023018816A2 (pt) 2023-10-31
EP4308553A4 (en) 2025-01-22
JP2024510260A (ja) 2024-03-06

Similar Documents

Publication Publication Date Title
IL305952A (en) Melanocortin subtype 2 receptor (MC2R) antagonist for disease treatment
EP3626270B1 (en) Treatment of cardiovascular diseases
JP2007508336A5 (https=)
JP2009536176A5 (https=)
EP4426298B1 (en) New therapeutic combinations comprising pirfenidone and pde4-inhibitor for the treatment of progressive fibrosing interstitial lung diseases
KR101168136B9 (ko) 혈압 강하용 약제학적 조성물
WO2018062134A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
AU2021255084B2 (en) Breast cancer therapeutic agent
RU2007119067A (ru) Средство для лечения синдрома раздраженного кишечника с преобладанием диареи
JP5922676B2 (ja) 悪心または嘔吐防止用組成物
KR101414814B1 (ko) 염산레르카니디핀 및 발사르탄을 포함하는 복합 제제 및 이의 제조방법
JP2023531930A5 (https=)
WO2021216678A1 (en) Renin-angiotensin system (ras) modulators for treatment of viral infections, pharmaceutical compositions including the same
KR20170118830A (ko) 조현병의 치료를 위한 일로페리돈
JP2012500248A (ja) 不安障害の治療
CN106061505A (zh) 用于治疗癌症的含pi3k抑制剂的药物组合
JP2019099579A5 (https=)
CN100453081C (zh) 用于治疗糖尿病性肾病的吡啶基亚磺酰氨基嘧啶
TW202122089A (zh) 肥大細胞疾病及嗜酸性病症之治療
CA2624025A1 (en) Regimen of administration for 5-(2-chlorophenyl)-1 ,2-dihydro-7-fluoro-8-methoxy-3-methyl-pyrazolo [3, 4.-b] [1, 4] benzodiazepine
US10391080B2 (en) Ketorolac for the treatment of cancer
JPWO2003047591A1 (ja) 肺高血圧症予防治療剤
HK40118402A (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
US10517851B2 (en) Vasopressin-like action enhancer
Sojitra et al. A review on Nifedipine co-administered with Metoprolol succinate for the treatment of hypertension